Sphera Funds Management’s Heron Therapeutics HRTX Stock Holding History

Sphera Funds Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-250,000	Closed	-$3.75M	–	131
2017 Q1	$3.75M	Buy	+250,000	New	+$3.46M	0.73%	38
2016 Q2	–	Sell	-100,000	Closed	-$1.9M	–	101
2016 Q1	$1.9M	Sell	100,000 -35,000	-26%	-$691K	0.41%	54
2015 Q4	$3.6M	Buy	135,000 +85,000	+170%	+$2.27M	0.53%	37
2015 Q3	$1.22M	Buy	+50,000	New	+$1.67M	0.16%	114
2015 Q2	–	Sell	-79,900	Closed	-$1.16M	–	144
2015 Q1	$1.16M	Buy	+79,900	New	+$901K	0.12%	131

Other funds holding HRTX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sphera Funds Management's HRTX Position: Q2 2017 in Review

Sphera Funds Management sold out of Heron Therapeutics (HRTX) in Q2 2017, closing a stake of 250,000 shares — an estimated $3.75M sold.

Sphera Funds Management first reported a position in HRTX in Q1 2015 and held it in 5 quarters. The position peaked at $3.75M in Q1 2017. 104 funds tracked by Wall St. Rank hold HRTX as of Q2 2017.

Sphera Funds Management reported no remaining Heron Therapeutics position as of Q2 2017 after selling out during the quarter.
Sphera Funds Management sold 250,000 Heron Therapeutics shares in Q2 2017, an estimated $3.75M.
Sphera Funds Management first reported a position in Heron Therapeutics in Q1 2015 and held it in 5 quarters.
Sphera Funds Management's Heron Therapeutics position peaked at $3.75M in Q1 2017.
104 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2017.

Based on Sphera Funds Management's 13F filing for Q2 2017, filed 9 Aug 2017.